[ad_1]
A drug that reverses the anticoagulant effects of factor Xa inhibitors has effectively stopped the acute bleeding that is life-threatening for patients taking hemorrhagic anticoagulant, according to a recent scientific study presented at the International Conference on the Features of the American Stroke Association 2019.
The study will be published simultaneously in the journal New England Journal of Medicine.
Factor Xa inhibitory anticoagulants (apixaban, rivaroxaban or edoxaban, direct Factor Xa inhibitors) and enoxaparin are used to prevent blood clots but may also cause or aggravate serious bleeding. The agent andexanet alfa is designed to rapidly neutralize the anticoagulant effects of anticoagulants in case of acute hemorrhage. The researchers investigated whether andexanet alfa could decrease the effect of the anticoagulant and bleeding evaluated 12 hours after the administration of the reversal agent.
A total of 352 patients (mean age 77 years, 53% male) were recruited from 86 sites worldwide, after presenting themselves with emergency gastrointestinal bleeding or bleeding cerebral. The researchers reported that 81.7% of patients had good or excellent haemostasis (stop bleeding).
"The study supported the FDA's May 2018 approval of andexanet alfa, which is now the only approved agent for patients taking rivaroxaban and apixaban when a Urgent weaning is necessary in case of life-threatening or uncontrolled bleeding, said lead author Truman J. Milling Jr., MD, badociate, professor in the department of neurology and badociate professor in the department of surgery and perioperative care Seton's Dell Medical School Stroke Institute in Austin, Texas.
A fast and effective antidote for bleeding related to anticoagulants
Provided by
American Heart Association
Quote:
Inverse agent reduces life-threatening bleeding (February 8, 2019)
recovered on February 8, 2019
on https://medicalxpress.com/news/2019-02-reversal-agent-decreases-life-threatening.html
This document is subject to copyright. Apart from any fair use for study or private research purposes, no
part may be reproduced without written permission. Content is provided for information only.
[ad_2]
Source link
